234 related articles for article (PubMed ID: 35816090)
1. Preclinical Studies of Natural Products Targeting the Gut Microbiota: Beneficial Effects on Diabetes.
Jiang X; Sun B; Zhou Z
J Agric Food Chem; 2022 Jul; 70(28):8569-8581. PubMed ID: 35816090
[TBL] [Abstract][Full Text] [Related]
2. Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus.
Liu W; Luo Z; Zhou J; Sun B
Front Cell Infect Microbiol; 2022; 12():853771. PubMed ID: 35711668
[TBL] [Abstract][Full Text] [Related]
3. Modulating the Gut Microbiota and Metabolites with Traditional Chinese Medicines: An Emerging Therapy for Type 2 Diabetes Mellitus and Its Complications.
Jiang P; Di Z; Huang W; Xie L
Molecules; 2024 Jun; 29(12):. PubMed ID: 38930814
[TBL] [Abstract][Full Text] [Related]
4. Bioactive Agent Discovery from the Natural Compounds for the Treatment of Type 2 Diabetes Rat Model.
Yang SC; Hsu CY; Chou WL; Fang JY; Chuang SY
Molecules; 2020 Dec; 25(23):. PubMed ID: 33287318
[TBL] [Abstract][Full Text] [Related]
5. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin.
Zhang C; Ma S; Wu J; Luo L; Qiao S; Li R; Xu W; Wang N; Zhao B; Wang X; Zhang Y; Wang X
Pharmacol Res; 2020 Sep; 159():104985. PubMed ID: 32504839
[TBL] [Abstract][Full Text] [Related]
6. Interactions between Gut Microbiota and Oral Antihyperglycemic Drugs: A Systematic Review.
Mindrescu NM; Guja C; Jinga V; Ispas S; Curici A; Nelson Twakor A; Pantea Stoian AM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542513
[TBL] [Abstract][Full Text] [Related]
7. Laurolitsine ameliorates type 2 diabetes by regulating the hepatic LKB1-AMPK pathway and gut microbiota.
Yong Z; Ruiqi W; Yanan Y; Ning M; Zhi Z; Yinfeng T; Lin D; Yiying L; Weiying L; Chongming W; Xiaopo Z
Phytomedicine; 2022 Nov; 106():154423. PubMed ID: 36075181
[TBL] [Abstract][Full Text] [Related]
8. New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes.
Chen Y; Wang M
Drug Des Devel Ther; 2021; 15():4849-4863. PubMed ID: 34876807
[TBL] [Abstract][Full Text] [Related]
9. Response of gut microbiota in type 2 diabetes to hypoglycemic agents.
Zhang F; Wang M; Yang J; Xu Q; Liang C; Chen B; Zhang J; Yang Y; Wang H; Shang Y; Wang Y; Mu X; Zhu D; Zhang C; Yao M; Zhang L
Endocrine; 2019 Dec; 66(3):485-493. PubMed ID: 31410749
[TBL] [Abstract][Full Text] [Related]
10. Microbiota: A potential orchestrator of antidiabetic therapy.
Liu B; Zhang L; Yang H; Zheng H; Liao X
Front Endocrinol (Lausanne); 2023; 14():973624. PubMed ID: 36777348
[TBL] [Abstract][Full Text] [Related]
11. Regulation of glucose metabolism by bioactive phytochemicals for the management of type 2 diabetes mellitus.
Zhao C; Yang C; Wai STC; Zhang Y; P Portillo M; Paoli P; Wu Y; San Cheang W; Liu B; Carpéné C; Xiao J; Cao H
Crit Rev Food Sci Nutr; 2019; 59(6):830-847. PubMed ID: 30501400
[TBL] [Abstract][Full Text] [Related]
12. Whole Alga, Algal Extracts, and Compounds as Ingredients of Functional Foods: Composition and Action Mechanism Relationships in the Prevention and Treatment of Type-2 Diabetes Mellitus.
Bocanegra A; Macho-González A; Garcimartín A; Benedí J; Sánchez-Muniz FJ
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917044
[TBL] [Abstract][Full Text] [Related]
13. Gut Microbiota Targeted Approach by Natural Products in Diabetes Management: An Overview.
Sati P; Dhyani P; Sharma E; Attri DC; Jantwal A; Devi R; Calina D; Sharifi-Rad J
Curr Nutr Rep; 2024 Jun; 13(2):166-185. PubMed ID: 38498287
[TBL] [Abstract][Full Text] [Related]
14. Editorial: Natural Compounds and Their Derivatives as a Source of Promising Drugs for Diabetes and Insulin Resistance.
Mena Barreto Silva FR; Silva Frederico MJ
Curr Drug Targets; 2017; 18(6):618. PubMed ID: 28831919
[No Abstract] [Full Text] [Related]
15. Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis.
Liao X; Song L; Zeng B; Liu B; Qiu Y; Qu H; Zheng Y; Long M; Zhou H; Wang Y; Du Y; Xu J; Shen R; Tong Q; Cai L; Li X; Guo S; Yang G; Zhu Z; Pu X; Wei H; Zheng H
EBioMedicine; 2019 Jun; 44():665-674. PubMed ID: 30922964
[TBL] [Abstract][Full Text] [Related]
16. The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus.
Lv Y; Zhao X; Guo W; Gao Y; Yang S; Li Z; Wang G
J Diabetes Res; 2018; 2018():1890978. PubMed ID: 29854817
[TBL] [Abstract][Full Text] [Related]
17. Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment.
Jia L; Huang S; Sun B; Shang Y; Zhu C
Front Endocrinol (Lausanne); 2023; 14():1149256. PubMed ID: 37033254
[TBL] [Abstract][Full Text] [Related]
18. Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota.
Cai T; Song X; Xu X; Dong L; Liang S; Xin M; Huang Y; Zhu L; Li T; Wang X; Fang Y; Xu Z; Wang C; Wang M; Li J; Zheng Y; Sun W; Li L
Front Cell Infect Microbiol; 2024; 14():1323261. PubMed ID: 38444539
[TBL] [Abstract][Full Text] [Related]
19. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus.
Zhou Z; Sun B; Yu D; Zhu C
Front Cell Infect Microbiol; 2022; 12():834485. PubMed ID: 35242721
[TBL] [Abstract][Full Text] [Related]
20. Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications.
Mahomoodally MF; Lobine D; Picot-Allain MCN; Sadeer N; Jugreet S; Zengin G
Curr Med Chem; 2021; 28(23):4638-4669. PubMed ID: 33138749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
